6 vs. 12 months of hormone therapy for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial compares two different lengths of hormone therapy (6 months vs. 12 months) combined with radiation for men with an intermediate-risk type of prostate cancer that is not favorable. The goal is to find out if a shorter treatment works just as well as the longer one, with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that was confirmed by biopsy in the last 6 months.
- Your cancer is an 'unfavorable intermediate-risk' type (your doctor can tell you this based on your PSA, Gleason score, and tumor stage).
- Scans (CT and bone scan) show the cancer has not spread to other parts of your body or to lymph nodes in the abdomen or pelvis.
- You have not had chemotherapy for prostate cancer before.
- You are in good overall health (ECOG score 0 or 1) and your blood counts and kidney function are within normal limits.
- Your prostate is not too large (75 cc or smaller on imaging).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of radiation (SBRT) and short-term hormone therapy (6 months) to see how it affects sexual function in men with unfavorable intermediate-risk prostate cancer.
This trial studies whether giving a shorter-course radiation plan after prostate surgery, along with hormone shots (LHRH), can improve outcomes for people with higher-risk prostate cancer. You may be eligible if your PSA (a blood marker) is either still low but high-risk by pathology, or it has started to rise again after surgery.
This trial tests whether a shorter course of hormone therapy (2 years) plus a new hormone drug (6 months) with radiation is as effective as longer treatment for high-risk prostate cancer that hasn't spread.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This trial studies a more sped-up radiation schedule for men with certain local prostate cancers, given together with hormone therapy. It aims to keep cancer control while possibly reducing treatment time and making care easier.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.